Dose-Response Relationship for External Workload and Neuromsuclar Performance Over a Female, Collegiate, Basketball Season

ABSTRACT

Philipp, NM, Cabarkapa, D, Blackburn, SD, and Fry, AC. Dose-response relationship for external workload and neuromsuclar performance over a female, collegiate, basketball season. J Strength Cond Res 38(5): e253-e263, 2024-The aim of this study was to investigate the relationship between external workload exposure and changes in countermovement jump force-time characteristics over the course of an entire basketball season, in a sample of National Collegiate Athletic Association Division I, female, basketball players. Data for 12 players were retrospectively analyzed, with external workload being quantified by means of an exponentially weighted, acute, and chronic workload, as well as an acute:chronic workload ratio derived from an inertial measurement unit-based system worn by athletes for all practices and games during the regular season. Countermovement jumps were performed on a total of 26 test days over the span of the in-season competitive period. To statistically analyze these relationships, and to account for multiple observations of the same athletes in a data set, linear mixed-effects models with athlete identity (ID) intercept as the random effect were used. Study findings suggested that associations between external workload exposure and respective force-time characteristics after controlling for the random effect of athlete ID were dependent on the specific metric or metric subgroup used, as well as the type of workload exposure (e.g., acute vs. chronic). Force-time signatures from the braking phase (e.g., average braking force) seemed to be particularly associated with higher degrees of acute workload exposure, whereas strategy-based metrics such as countermovement depth showed significant associations with chronic workload exposure. Furthermore, model results suggested the importance of analyzing neuromuscular responses to external workload on an individual basis, rather than across an entire team. Findings might help practitioners in their selection process related to metrics of interest in monitoring neuromuscular fatigue and readiness.

Vertical Jump Neuromuscular Performance Characteristics Determining On-Court Contribution in Male and Female NCAA Division 1 Basketball Players

While various quantifiable physical attributes have been found to contribute to athletes' performance, there is a lack of scientific literature focused on examining how they relate to success during competition performance. The aim of this study was to investigate different countermovement jump (CMJ)-derived force-time characteristics and their utility in distinguishing high from low performers within a measure of on-court contribution (i.e., minutes per game played). Twenty-nine collegiate athletes (n = 15 males and n = 14 females) volunteered to participate in this investigation and performed CMJs on dual force plates sampling at 1000 Hz, weekly over the course of their basketball season. The athletes' average of their three best test-days across the season was used for further analysis. To identify their on-court contribution, athletes were divided into groups with high and low minutes per game, based on a median-split analysis. The findings suggest that at the overall group level (i.e., both genders), the modified reactive strength index (mRSI) and braking rate of force development (RFD) revealed the greatest between-group magnitudes of difference, with athletes playing more minutes per game showing greater performance. At the team-specific level, the braking RFD, average braking velocity, and mRSI were shown to be the greatest differentiators between groups for the men's team. The women's high-minutes group displayed greater magnitudes of mRSI and jump height. By identifying the neuromuscular qualities seen in top performers within their respective populations, the attributed physical performance underpinning these qualities may be identified, providing practitioners with insights into physical performance qualities and training methodologies that have the potential to influence basketball performance.

Attachment of adeno-associated virus type 3H to fibroblast growth factor receptor 1

Heparan sulfate proteoglycan is thought to act as primary receptor for adeno-associated virus type 2 (AAV-2). Reported coreceptors include alphaVbeta5 integrin, fibroblast growth factor receptor 1 (FGFR-1), and hepatocyte growth factor (c-Met). The interaction of AAV type 3 (AAV-3) with possible cell membrane receptors is incompletely defined. In this study, using assays detecting competition with viral infection, virus binding inhibition assays and dot blotting, we show attachment of AAV-3 strain H to heparin, heparan sulfate, and FGFR-1. These findings provide new information on the possible receptor array used by AAV-3.

Attachment of bovine parvovirus to O-linked alpha 2,3 neuraminic acid on glycophorin A

The bovine parvovirus (BPV) hemagglutinates human erythrocytes by binding to glycophorin A (GPA). The purpose of this study was to determine which carbohydrate on GPA binds BPV. Treatment of GPA with alpha2,3,-6,-8 neuraminidase eliminated binding of BPV to GPA. Beta-elimination of O-linked sialic acids on GPA eliminated binding, while removal of N-linked carbohydrates using the N-glycosidase PNGase F failed to eliminate binding. Treatment of GPA with a neuraminidase which specifically cleaved alpha2,3 glycosidic bonds eliminated BPV binding and, following this treatment, virus binding to GPA was restored by reconstitution of alpha2,3-linked neuraminic acids. These results indicated the O-linked alpha2,3 neuraminic acids of GPA bind BPV.

Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension

BACKGROUND

Primary pulmonary hypertension results from progressive narrowing of the precapillary pulmonary vasculature. A variety of endothelial abnormalities have been identified, including a net reduction in pulmonary clearance of the vasoconstrictor and smooth muscle mitogen endothelin-1. In many patients, net pulmonary release of endothelin-1 is observed. Chronic infusions of epoprostenol (prostacyclin) improve functional capacity, survival, and hemodynamics in patients with advanced primary pulmonary hypertension. We hypothesized that the epoprostenol infusions, as compared with conventional therapy, might alter the abnormal pulmonary endothelin-1 homeostasis.

METHODS AND RESULTS

Using a subset of patients from a larger randomized study comparing epoprostenol plus conventional therapy (n=11 in the present study) with conventional therapy alone (n=7 in the present study), we determined the ratio of plasma endothelin-1 levels in systemic arterial blood leaving the lung to levels in mixed venous blood entering the lung both before randomization and after 88 days of continuous therapy. There were no differences between the 2 groups before therapy, but by day 88, the epoprostenol-treated group had a greater proportion of patients (82%) with an arterial/venous ratio <1 than did the conventional therapy group, in which only 29% of patients had a ratio <1 (P<0.05).

CONCLUSIONS

These results suggest that continuous epoprostenol therapy may have a beneficial effect on the balance between endothelin-1 clearance and release in many patients with primary pulmonary hypertension and may provide one explanation for the salutary effect of epoprostenol in this disease.

Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group

BACKGROUND

Right heart failure is an important cause of morbidity and mortality in primary pulmonary hypertension. In a recent prospective, randomized study of severely symptomatic patients, treatment with prostacyclin (epoprostenol) produced improvements in hemodynamics, quality of life, and survival. This article describes the echocardiographic characteristics of participants in this trial; the relationship of echocardiographic variables to hemodynamic parameters, exercise capacity, and quality of life; and the echocardiographic changes associated with prostacyclin therapy.

METHODS AND RESULTS

The 81 patients enrolled in this multicenter trial were randomized to treatment with a long-term infusion of prostacyclin in addition to conventional therapy (n = 41) or conventional therapy alone (n = 40) for 12 weeks. Echocardiograms and assessments of hemodynamics, exercise capacity, and quality of life were performed before and after the treatment phase. On baseline evaluation, patients had marked right ventricular dilatation and dysfunction, abnormal septal curvature, and significant tricuspid regurgitation with a high regurgitant velocity. Pericardial effusions were common. More pronounced abnormalities in right heart structure and function were associated with higher pulmonary arterial and mean right atrial pressures, lower cardiac index, and impaired exercise capacity but had no predictable relationship to quality-of-life indicators. The 12-week infusion of prostacyclin had beneficial effects on right ventricular size, curvature of the interventricular septum, and maximal tricuspid regurgitant jet velocity.

CONCLUSIONS

The echocardiographic manifestations of severe primary pulmonary hypertension reflect abnormalities in hemodynamics and exercise capacity. Prostacyclin has beneficial effects on right heart structure and function that may contribute to the clinical improvement and prolonged survival observed with this drug.

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

BACKGROUND

Primary pulmonary hypertension is a progressive disease for which no treatment has been shown in a prospective, randomized trial to improve survival.

METHODS

We conducted a 12-week prospective, randomized, multicenter open trial comparing the effects of the continuous intravenous infusion of epoprostenol (formerly called prostacyclin) plus conventional therapy with those of conventional therapy alone in 81 patients with severe primary pulmonary hypertension (New York Heart Association functional class III or IV).

RESULTS

Exercise capacity was improved in the 41 patients treated with epoprostenol (median distance walked in six minutes, 362 m at 12 weeks vs. 315 m at base line), but it decreased in the 40 patients treated with conventional therapy alone (204 m at 12 weeks vs. 270 m at base line; P < 0.002 for the comparison of the treatment groups). Indexes of the quality of life were improved only in the epoprostenol group (P < 0.01). Hemodynamics improved at 12 weeks in the epoprostenol-treated patients. The changes in mean pulmonary-artery pressure for the epoprostenol and control groups were -8 percent and +3 percent, respectively (difference in mean change, -6.7 mm Hg; 95 percent confidence interval, -10.7 to -2.6 mm Hg; P < 0.002), and the mean changes in pulmonary vascular resistance for the epoprostenol and control groups were -21 percent and +9 percent, respectively (difference in mean change, -4.9 mm Hg/liter/min; 95 percent confidence interval, -7.6 to -2.3 mm Hg/liter/min; P < 0.001). Eight patients died during the study, all of whom had been randomly assigned to conventional therapy (P = 0.003). Serious complications included four episodes of catheter-related sepsis and one thrombotic event.

CONCLUSIONS

As compared with conventional therapy, the continuous intravenous infusion of epoprostenol produced symptomatic and hemodynamic improvement, as well as improved survival in patients with severe primary pulmonary hypertension.